EP Patent

EP2570127A1 — Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors

Assigned to Sanofi SA · Expires 2013-03-20 · 13y expired

What this patent protects

The present invention relates to compositions comprising at least one MAPK pathway inhibitor including MEK and RAF inhibitors and at least one PI3Kβ inhibitor, and also to uses thereof for the treatment of cancer.

USPTO Abstract

The present invention relates to compositions comprising at least one MAPK pathway inhibitor including MEK and RAF inhibitors and at least one PI3Kβ inhibitor, and also to uses thereof for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2570127A1
Jurisdiction
EP
Classification
—
Expires
2013-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.